AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2019 Issue 4; Section X - New Technology

New Therapeutic Substances

Eleven new substance values were added to code table XW0, Anatomical Regions, Introduction, as noted below. Device/Substance/TechnologyJ Apalutamide Antineoplastic K Fosfomycin Anti-infective L Erdafitinib Antineoplastic N Meropenem-vaborbactam Anti-infective Q Tagraxofusp-erzs Antineoplastic R Venetoclax Antineoplastic S Iobenguane I-131Antineoplastic T Ruxolitinib U Imipenem-cilastatin-relebactam Anti-infective V Gilteritinib Antineoplastic W Caplacizumab Apalutamide Antineoplastic Apalutamide, also known by its trade name ERLEADA™, is an oral androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Prostate cancer that has not spread to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone...

To read the full article, sign in and subscribe to AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS .


  • The official AHA publication for ICD-10-CM and ICD-10-PCS coding guidelines and advice
  • Current newsletters added each quarter
  • Full Archives - over 3100 articles
  • ALL years/issues back to 1984 organized by year and issue
  • Includes ICD-10-CM/PCS Articles since 2013
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - ICD-10-CM/PCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.